TY  - GEN
AU  - Juergens,Rosalyn A
AU  - Hao,Desiree
AU  - Ellis,Peter M
AU  - Tu,Dongsheng
AU  - Mates,Mihaela
AU  - Kollmannsberger,Christian
AU  - Bradbury,Penelope A
AU  - Tehfe,Moustapha
AU  - Wheatley-Price,Paul
AU  - Robinson,Andrew
AU  - Bebb,Gwyn
AU  - Laskin,Janessa
AU  - Goffin,John
AU  - Hilton,John
AU  - Tomiak,Anna
AU  - Hotte,Sebastien
AU  - Goss,Glenwood D
AU  - Brown-Walker,Pamela
AU  - Sun,Xiaoqun
AU  - Tsao,Ming-Sound
AU  - Cabanero,Michael
AU  - Gauthier,Isabelle
AU  - Song,Xuyang
AU  - Dennis,Phillip A
AU  - Seymour,Lesley K
AU  - Smoragiewicz,Martin
AU  - Laurie,Scott A
TI  - A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226
SN  - 1872-8332
PY  - 2021///0412
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Carboplatin
KW  - Cisplatin
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Neoplasms
KW  - drug therapy
KW  - Prognosis
KW  - Survival Rate
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.lungcan.2020.02.016
ER  -